New Oncology and Gustave Roussy announce collaboration on genetic testing
14 October 2014 | By New Oncology
New Oncology announced that it has entered into a collaboration agreement with Gustave Roussy Cancer Campus, Paris...
List view / Grid view
News
Rigontec GmbH raises €9.45m in a first closing of a Series A financing round to advance RNA-based immunotherapeutics for cancer and viral diseases
14 October 2014 | By Rigontec GmbH
Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announces the first closing of its Series A financing round, raising €9.45 million...
Cardio3 Biosciences receives authorization to enroll patients in Switzerland in its Phase iii clinical trial CHART-1
14 October 2014 | By Cardio3 BioSciences
Cardio3 BioSciences announces it has received authorization from Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C-Cure® in Switzerland...
BioVigilant introduces Instantaneous Microbial Detection for pharmaceutical water monitoring
14 October 2014 | By Azbil BioVigilant
Azbil BioVigilant, inventors of Instantaneous Microbial Detection™, announced the introduction of its new IMD-W™ rapid microbial detection system for real-time water monitoring of pharmaceutical water sources...
Bristol-Myers Squibb, Pharmacyclics and Janssen announce clinical collaboration to evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in non-Hodgkin lymphoma
13 October 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (NYSE:BMY), Pharmacyclics, Inc. (NASDAQ:PCYC), and Janssen Research & Development, LLC announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO® (nivolumab) in combination with IMBRUVICA® (ibrutinib), an oral Bruton's…
Bristol-Myers Squibb to hold investor teleconference to discuss CMSTO highlights
13 October 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company will host a teleconference on Friday, October 31, 2014, at 2:30 p.m. EDT (1:30 p.m. CDT) to review data presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology (CMSTO) in Chicago...
Probiodrug launches its Initial Public Offering and listing on Euronext Amsterdam
13 October 2014 | By Probiodrug AG
Probiodrug AG announces the launch of its Initial Public Offering and listing on Euronext Amsterdam...
Evotec receives milestone as part of its multi-target alliance with Bayer HealthCare
13 October 2014 | By Evotec
Evotec AG announced that its multi-target collaboration with Bayer HealthCare has reached an important milestone for the transition of a molecule into pre-clinical development for the treatment of endometriosis...
ABPI and OBN announce Memorandum of Understanding
13 October 2014 | By ABPI and OBN
The ABPI, which represents large, medium and small innovative research-based biopharmaceutical companies in the UK and OBN, the membership organisation that brings together the UK’s emerging life sciences companies, corporate partners and investors are delighted to announce their commitment to working together under a Memorandum of Understanding...
Ulcerative colitis patients who have had a colectomy continue to experience symptoms and nearly half say if they could go back in time, they would want more information on the treatment choices
13 October 2014 | By MSD
NICE draft guidance says no to biologic treatments for patients with moderate-to-severe ulcerative colitis – potentially missing the opportunity to provide an alternative...
TacticID-N used to ID illegal mixed street tablets as part of joint federal task force take downs
10 October 2014 | By B&W Tek
B&W Tek, Inc. is pleased to announce that our newest handheld Raman system, the TacticID-N, has recently received some exceptional praise from a United States federal law enforcement agency...
Janssen demonstrates continued commitment to combating Hepatitis C in European patients with data presented at Viral Hepatitis Congress
10 October 2014 | By Janssen
New data demonstrates efficacy and safety of OLYSIO® (simeprevir) in broader patient populations...
New findings from the Psoriasis Longitudinal Assessment and registry (PSOLAR) show persistency difference among biologic therapies
10 October 2014 | By Janssen
Persistence of STELARA® (ustekinumab) significantly better than Anti-TNFs in treatment of Psoriasis according to observational study analysis...
Advanced Cell Diagnostics awarded $1.4 million NCI Grant to develop ultrasensitive diagnostic test for B-cell lymphoma
10 October 2014 | By Advanced Cell Diagnostics, Inc
Advanced Cell Diagnostics, Inc. has been awarded a two-year, $1.4 million grant from National Cancer Institute...
From stem cells to billions of human insulin-producing cells
10 October 2014 | By The Harvard Stem Cell Institute
Giant step toward new diabetes treatment...
